Suppr超能文献

淋巴瘤患者接受嵌合抗原受体 T 细胞(CAR T)治疗后出现 18F-FDG PET 早期flare-up 现象。

Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.

机构信息

From the Department of Nuclear Medicine and Nancyclotep Imaging Platform.

Department of Hematology, Université de Lorraine, CHRU Nancy.

出版信息

Clin Nucl Med. 2022 Feb 1;47(2):e152-e153. doi: 10.1097/RLU.0000000000003870.

Abstract

18F-FDG PET/CT imaging series were acquired on a 64-year-old woman with refractory diffuse large B lymphoma to monitor chimeric antigen receptor (CAR) T-cell therapy. Because of a clinical deterioration, 18F-FDG PET/CT performed 8 days after CAR T-cell therapy suggested an early flare-up phenomenon with new lymph node involvement, lymph node progression while a decrease in metabolic tumor volume. The 18F-FDG PET/CT 1 month after CAR T-cell therapy confirmed this hypothesis. Pseudoprogression in solid tumors treated by immunotherapy has generally been reported later after treatment.

摘要

我们对一名难治性弥漫性大 B 细胞淋巴瘤老年女性患者进行了 18F-FDG PET/CT 系列检查,以监测嵌合抗原受体(CAR)T 细胞治疗效果。由于病情恶化,CAR T 细胞治疗后 8 天进行的 18F-FDG PET/CT 检查提示出现早期爆发现象,伴有新的淋巴结受累、淋巴结进展,同时代谢肿瘤体积减少。CAR T 细胞治疗 1 个月后的 18F-FDG PET/CT 检查结果证实了这一假说。免疫治疗治疗后的实体瘤假性进展通常在治疗后较晚出现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验